抗骨质疏松治疗药物研究的新进展
投稿时间:2017-08-24  最后修改时间:2017-10-16  点此下载全文
引用本文:贾文斌,刘超,邹燕.抗骨质疏松治疗药物研究的新进展[J].药学实践杂志,2017,35(6):490~494,542
摘要点击次数: 61
全文下载次数: 62
作者单位E-mail
贾文斌 海军青岛第一疗养院药剂科, 山东 青岛 266071  
刘超 第二军医大学药学院有机化学教研室, 上海 200433  
邹燕 第二军医大学药学院有机化学教研室, 上海 200433 zouyan@smmu.edu.cn 
中文摘要:骨质疏松是一种常见的全身性骨代谢疾病,主要表现为骨密度与骨量的下降,从而导致继发性骨折。目前,随着其发病率不断增高,骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞,通过抑制破骨细胞分化成熟,减少骨吸收;骨形成促进剂主要作用于成骨细胞,激活其骨形成功能,并且有重建骨组织的效应;骨矿化物是防治骨质疏松的基础药物,包括钙剂和维生素D;解偶联剂种类较为单一,代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。
中文关键词:骨质疏松  药物  治疗  骨吸收抑制剂  骨形成促进剂  骨矿化促进剂
 
Research progress on drugs in osteoporosis therapy
Abstract:Osteoporosis (OP) is a systemic bone metabolism disease characterized by a systemic impairment of bone mass, strength, and microarchitecture, which will be result in increasing the propensity of fragility fractures. In recent years, OP becomes a worldwide health problem and a hotspot in medical research due to its increasing incidence. Anti-resorptive drugs inhibit osteoclast differentiation and maturation in order to reduce bone resorption; Bone-anabolic drugs promote the bone formation function of osteoblast and reconstruct bone tissue; Bone mineralization-acceleration drugs are the basic material for prevention and treatment of osteoporosis, including calcium and vitamin D; Strontium ranelate is the representative drug of uncoupling agents. In this paper, the current progress of osteoporosis treatments were reviewed including these proposed drugs.
keywords:osteoporosis  drugs  therapy  anti-resorptive drugs  bone-anabolic drugs  bone mineralization-acceleration drugs
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮